{"id":45780,"date":"2025-11-04T22:02:47","date_gmt":"2025-11-04T14:02:47","guid":{"rendered":"https:\/\/flcube.com\/?p=45780"},"modified":"2025-11-04T22:02:47","modified_gmt":"2025-11-04T14:02:47","slug":"eli-lilly-announces-phase-3-attain%e2%80%91pad-trial-for-oral-glp%e2%80%911-agent-orforglipron","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45780","title":{"rendered":"Eli Lilly Announces Phase\u202f3 ATTAIN\u2011PAD Trial for Oral GLP\u20111 Agent orforglipron"},"content":{"rendered":"\n<p>Eli Lilly (<a href=\"https:\/\/www.google.com\/finance\/quote\/LLY:NYSE\">NYSE: LLY<\/a>), a global biopharma titan, will commence the ATTAIN\u2011PAD phase\u202f3 study\u2014an ambitious, patient\u2011enriched trial testing its once\u2011daily oral small\u2011molecule GLP\u20111 receptor agonist, <strong>orforglipron<\/strong>, in the treatment of <strong>peripheral artery disease (PAD)<\/strong>. The multi\u2011center trial will recruit <strong>1,205 patients<\/strong> with Fontaine Stage\u202fII disease and is slated for completion in <strong>June\u202f2028<\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-what-orforglipron-brings-to-the-pad-landscape\">What Orforglipron Brings to the PAD Landscape<\/h3>\n\n\n\n<p>Orforglipron is a non\u2011peptide, orally disintegrating small\u2011molecule GLP\u20111 RA that offers remarkable dosing flexibility\u2014patients can take it any time of day, regardless of meals or fluids. The compound was first identified by <strong>Chugai Pharmaceutical Co., Ltd.<\/strong>, before Lilly secured a development license in 2018.<\/p>\n\n\n\n<p>Previous phase\u202f3 studies (ACHIEVE\u20111 &amp; ACHIEVE\u20113) already delivered topline success, showing superior reductions in glycated hemoglobin (A1C), beta\u2011cell preservation, and weight loss compared to the benchmark GLP\u20111 RA, semaglutide (7\u202fmg and 14\u202fmg).<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-attain-pad-a-milestone-for-cardiovascular-therapeutics\">ATTAIN\u2011PAD: A Milestone for Cardiovascular Therapeutics<\/h3>\n\n\n\n<p>The ATTAIN\u2011PAD study will test orforglipron\u2019s efficacy in improving limb perfusion and walking distance in the largest PAD cohort to date. With 1,205 participants across North and South American sites, the trial will provide robust data on cardiovascular safety and potential morbidity benefits.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-investment-outlook\">Investment Outlook<\/h3>\n\n\n\n<p>Eli\u202fLilly\u2019s entry into the PAD arena underscores the broader shift toward oral GLP\u20111 therapies for cardio\u2011metabolic conditions. Investors will be watching the <strong>2028<\/strong> completion dates for any pivotal data that could broaden orforglipron\u2019s indication portfolio and compete with existing GLP\u20111 RA offerings.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly (NYSE: LLY), a global biopharma titan, will commence the ATTAIN\u2011PAD phase\u202f3 study\u2014an ambitious,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":45781,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[382,62,199,4361,911],"class_list":["post-45780","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-chugai-pharmaceutical","tag-clinical-trial-approval-initiation","tag-eli-lilly","tag-hot-targets","tag-nyse-lly"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eli Lilly Announces Phase\u202f3 ATTAIN\u2011PAD Trial for Oral GLP\u20111 Agent orforglipron - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eli Lilly (NYSE: LLY), a global biopharma titan, will commence the ATTAIN\u2011PAD phase\u202f3 study\u2014an ambitious, patient\u2011enriched trial testing its once\u2011daily oral small\u2011molecule GLP\u20111 receptor agonist, orforglipron, in the treatment of peripheral artery disease (PAD). The multi\u2011center trial will recruit 1,205 patients with Fontaine Stage\u202fII disease and is slated for completion in June\u202f2028.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45780\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly Announces Phase\u202f3 ATTAIN\u2011PAD Trial for Oral GLP\u20111 Agent orforglipron\" \/>\n<meta property=\"og:description\" content=\"Eli Lilly (NYSE: LLY), a global biopharma titan, will commence the ATTAIN\u2011PAD phase\u202f3 study\u2014an ambitious, patient\u2011enriched trial testing its once\u2011daily oral small\u2011molecule GLP\u20111 receptor agonist, orforglipron, in the treatment of peripheral artery disease (PAD). The multi\u2011center trial will recruit 1,205 patients with Fontaine Stage\u202fII disease and is slated for completion in June\u202f2028.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45780\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-04T14:02:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0412.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45780#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45780\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly Announces Phase\u202f3 ATTAIN\u2011PAD Trial for Oral GLP\u20111 Agent orforglipron\",\"datePublished\":\"2025-11-04T14:02:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45780\"},\"wordCount\":259,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45780#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0412.webp\",\"keywords\":[\"Chugai Pharmaceutical\",\"Clinical trial approval \\\/ initiation\",\"Eli Lilly\",\"Hot targets\",\"NYSE: LLY\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45780#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45780\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45780\",\"name\":\"Eli Lilly Announces Phase\u202f3 ATTAIN\u2011PAD Trial for Oral GLP\u20111 Agent orforglipron - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45780#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45780#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0412.webp\",\"datePublished\":\"2025-11-04T14:02:47+00:00\",\"description\":\"Eli Lilly (NYSE: LLY), a global biopharma titan, will commence the ATTAIN\u2011PAD phase\u202f3 study\u2014an ambitious, patient\u2011enriched trial testing its once\u2011daily oral small\u2011molecule GLP\u20111 receptor agonist, orforglipron, in the treatment of peripheral artery disease (PAD). The multi\u2011center trial will recruit 1,205 patients with Fontaine Stage\u202fII disease and is slated for completion in June\u202f2028.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45780#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45780\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45780#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0412.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0412.webp\",\"width\":1080,\"height\":608,\"caption\":\"Eli\u202fLilly Announces Phase\u202f3 ATTAIN\u2011PAD Trial for Oral GLP\u20111 Agent orforglipron\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45780#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly Announces Phase\u202f3 ATTAIN\u2011PAD Trial for Oral GLP\u20111 Agent orforglipron\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly Announces Phase\u202f3 ATTAIN\u2011PAD Trial for Oral GLP\u20111 Agent orforglipron - Insight, China&#039;s Pharmaceutical Industry","description":"Eli Lilly (NYSE: LLY), a global biopharma titan, will commence the ATTAIN\u2011PAD phase\u202f3 study\u2014an ambitious, patient\u2011enriched trial testing its once\u2011daily oral small\u2011molecule GLP\u20111 receptor agonist, orforglipron, in the treatment of peripheral artery disease (PAD). The multi\u2011center trial will recruit 1,205 patients with Fontaine Stage\u202fII disease and is slated for completion in June\u202f2028.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45780","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly Announces Phase\u202f3 ATTAIN\u2011PAD Trial for Oral GLP\u20111 Agent orforglipron","og_description":"Eli Lilly (NYSE: LLY), a global biopharma titan, will commence the ATTAIN\u2011PAD phase\u202f3 study\u2014an ambitious, patient\u2011enriched trial testing its once\u2011daily oral small\u2011molecule GLP\u20111 receptor agonist, orforglipron, in the treatment of peripheral artery disease (PAD). The multi\u2011center trial will recruit 1,205 patients with Fontaine Stage\u202fII disease and is slated for completion in June\u202f2028.","og_url":"https:\/\/flcube.com\/?p=45780","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-04T14:02:47+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0412.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45780#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45780"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly Announces Phase\u202f3 ATTAIN\u2011PAD Trial for Oral GLP\u20111 Agent orforglipron","datePublished":"2025-11-04T14:02:47+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45780"},"wordCount":259,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45780#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0412.webp","keywords":["Chugai Pharmaceutical","Clinical trial approval \/ initiation","Eli Lilly","Hot targets","NYSE: LLY"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45780#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45780","url":"https:\/\/flcube.com\/?p=45780","name":"Eli Lilly Announces Phase\u202f3 ATTAIN\u2011PAD Trial for Oral GLP\u20111 Agent orforglipron - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45780#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45780#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0412.webp","datePublished":"2025-11-04T14:02:47+00:00","description":"Eli Lilly (NYSE: LLY), a global biopharma titan, will commence the ATTAIN\u2011PAD phase\u202f3 study\u2014an ambitious, patient\u2011enriched trial testing its once\u2011daily oral small\u2011molecule GLP\u20111 receptor agonist, orforglipron, in the treatment of peripheral artery disease (PAD). The multi\u2011center trial will recruit 1,205 patients with Fontaine Stage\u202fII disease and is slated for completion in June\u202f2028.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45780#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45780"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45780#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0412.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0412.webp","width":1080,"height":608,"caption":"Eli\u202fLilly Announces Phase\u202f3 ATTAIN\u2011PAD Trial for Oral GLP\u20111 Agent orforglipron"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45780#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly Announces Phase\u202f3 ATTAIN\u2011PAD Trial for Oral GLP\u20111 Agent orforglipron"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0412.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45780","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45780"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45780\/revisions"}],"predecessor-version":[{"id":45782,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45780\/revisions\/45782"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45781"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45780"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45780"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45780"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}